MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib

Leukemia

Volumn 29, Issue 3, 2015, Pages 727-738

  Jagannathan, S ^a   Vad, N ^a   Vallabhapurapu, S ^a   Anderson, K C ^b   Driscoll, J J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; BORTEZOMIB; CARFILZOMIB; IXAZOMIB; LENTIVIRUS VECTOR; MICRORNA 29A; MICRORNA 29B; PROTEASOME; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MICRORNA; MIRN29 MICRORNA, HUMAN; NUCLEAR PROTEIN; ORNITHINE DECARBOXYLASE; PROTEASOME ACTIVATOR 200 KDA, HUMAN; PYRAZINE DERIVATIVE; SMALL INTERFERING RNA;

AGGRESOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS ASSAY; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELL DEATH; CELL FRACTIONATION; CELL LYSATE; CELL VIABILITY; COMPARATIVE STUDY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MOUSE; MYELOMA; MYELOMA CELL; NATIVE POLYACRYLAMIDE GEL ELECTROPHORESIS; NONHUMAN; NORTHERN BLOTTING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; APOPTOSIS; CANCER TRANSPLANTATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; LENTIVIRINAE; METABOLISM; MORTALITY; MULTIPLE MYELOMA; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHAGOSOME; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; SURVIVAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; BORTEZOMIB; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED NOD; MICRORNAS; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; ORNITHINE DECARBOXYLASE; PHAGOSOMES; PRIMARY CELL CULTURE; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS;

EID: 84924359174     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.279     Document Type: Article

References (51)

1. Ameres SL, Zamore PD. Diversifying microRNA sequence and function. Nat Rev Mol Cell Biol 2013; 14: 475-488.
2. Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature 2014; 505: 344-352.
3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
5. Song SJ, Ito K, Ala A, Kats L, Webster K, Sun SM et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 2013; 13: 87-101.
6. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010; 70: 7027-7030.
7. Gallastegui N, Groll M. The 26S proteasome: assembly and function of a destructive machine. Trends Biochem Sci 2010; 35: 634-642.
8. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
9. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-3076.
10. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364: 1046-1060.
11. Nalepa G, Rolfe M, Harper W. Drug discovery in the ubiquitin-proteasome system. Nat Rev Drug Discov 2006; 5: 596-613.
12. Richardson PG, Schlossman RL, Alsina M, Weber DM, Coutre SE, Gasparetto C et al. PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013; 122: 2331-2337.
13. Orlowski R. Why proteasome inhibitors cannot ERADicate multiple myeloma. Cancer Cell 2013; 24: 275-277.
14. Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013; 24: 289-304.
15. Bence NF, Bennett EJ, Kopito RR. Application and analysis of the GFPu family of ubiquitin-proteasome system reporters. Methods Enzymol 2005; 399: 481-490.
16. Badr CE, Niers JM, Tjon-Kon-Fat LA, Noske DP, Wurdinger T, Tannous BA et al. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol Imaging 2009; 8: 278-290.
17. Tannous BA. Gaussia luciferase reporter assay for monitoring of biological processes in culture and in vivo. Nat Protoc 2009; 4: 582-591.
18. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006; 103: 2257-2261.
19. Migliore C, Giordanom S. Resistance to targeted therapies: a role for microRNAs? Trends Molecular Medicine 2013; 19: 633-642.
20. Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 2011; 292: 1552-1555.
21. Liu S, Wu L-C, Pang J, Santhanam R, Schwind S, Wu Y-Z. Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333-347.
22. Hwang HW, Wentzel EA, Mendell JT. A hexanucleotide element directs microRNA nuclear import. Science 2007; 315: 97-100.
23. Fehlker M, Wendler P, Lehmann A, Enenkel C. Blm3 is part of nascent proteasomes and is involved in a late stage of nuclear proteasome assembly. EMBO Rep. 2003; 4: 959-963.
24. Schmidt M, Haas W, Crosas B, Santamaria PG, Gygi SP, Walz T et al. The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle. Nat Struct Mol Biol 2005; 12: 294-303.
25. Blickwedehl J, Agarwal M, Seong C, Pandita RK, Melendy T, Sung P et al. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc Natl Acad Sci USA 2008; 105: 16165-16170.
26. Lehmann A, Jechow K, Enenkel C. Blm10 binds to pre-activated proteasome core particles with open gate conformation. EMBO Rep 2008; 9: 1237-1243.
27. Khor B, Bredemeyer AL, Huang CY, Turnbull IR, Evans R, Maggi LB et al. Proteasome activator PA200 is required for normal spermatogenesis. Mol Cell Biol 2006; 26: 2999-3007.
28. Sadre-Bazzaz K, Whitby FG, Robinson H, Formosa T, Hill CP. Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. Mol Cell 2010; 27: 728-735.
29. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. Recognition of the polyubiquitin proteolytic signal. EMBO J 2000; 19: 94-102.
30. Verma R, Deshaies RJ. A proteasome howdunit: The case of the missing signal. Cell 2000; 101: 341-344.
31. Ghoda L, van Daalen Wetters T, Macrae M, Ascherman D, Coffino P. Prevention of rapid intracellular degradation of ODC by a carboxyl-terminal truncation. Science 1989; 243: 1493-1495.
32. Stadtmueller BM, Hill CJ. Proteasome activators. Mol Cell 2011; 41: 8-19.
33. Savulescu AF, Glickmann M. Proteasome activator 200: the heat is on. Mol Cell Proteomics 2011; 10: R110.006890.
34. Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311-5321.
35. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817-2825.
36. Dick LR, Fleming PE. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov Today 2010; 15: 243-249.
37. Kumar S, Rajkumar SV. Many facets of bortezomib resistance susceptibility. Blood 2008; 112: 2177-2178.
38. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 2008; 112: 2489-2499.
39. Book AJ, Gladman NP, Lee SS, Scalf M, Smith LM, Vierstra RD. Affinity purification of the Arabidopsis 26S proteasome reveals a diverse array of plant proteolytic complexes. J Biol Chem 2010; 285: 25554-25569.
40. Hoyt MA, Coffino P. Ubiquitin-free routes into the proteasome. Cell Mol Life Sci 2004; 61: 1596-1600.
41. Hideshima T, Bradner JE, Wong J. Small molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA 2005; 102: 8567-8572.
42. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome Induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441-3449.
43. Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S et al. A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Blood 2011; 118: 6274-628340.
44. David E, Kaufman JL, Flowers CR, Schafer-Hales K, Torre C, Chen J, Marcus AI, Sun SY, Boise LH, Lonial S. Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes. Blood 2010; 116: 5285-5288.
45. Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F et al. microRNA expression in the biology, prognosis, and therapy of Waldenstrom macroglobulinemia. Blood 2009; 113: 4391-4402.
46. Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 2009; 13: 6669-6680.
47. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
48. Bader AG. miR-34- a microRNA replacement therapy is headed to the clinic. Front Genet 2012; 3: 1-9.
49. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010; 70: 5923-5930.
50. Ahmad N, Haider S, Anaissie E, Driscoll JJ. MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia 2014; 28: 732-738.
51. Das AT, Zhou X, Vink M, Klaver B, Verhoef K, Marzio G et al. Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 2004; 229: 18776-18782.